SetupAI
繁
SourceStalecollected in 12m

Isomorphic Labs seeks $2B+ funding round

Read original on 36氪
#funding#ai-biotech#drug-discovery

DeepMind AI drug firm chasing $2B fund—biotech AI scale signal

30-Second TL;DR

What Changed

In talks for >$2B funding round led by Thrive Capital.

Why It Matters

Massive funding underscores AI's push into biotech, potentially accelerating drug discovery pipelines for investors and partners.

What To Do Next

Evaluate Isomorphic's AlphaFold integrations for your protein folding drug pipelines.

Who should care:Researchers & Academics

Key Points

  • •In talks for >$2B funding round led by Thrive Capital.
  • •Alphabet (Google parent) to join the round.
  • •AI drug R&D company spun from DeepMind.

Deep Insight

AI-generated analysis for this event — not the original article.

Enhanced Key Takeaways

  • •The funding round is reportedly aimed at accelerating the development of Isomorphic's proprietary 'AlphaFold 3' platform, which extends beyond protein structure prediction to model interactions with DNA, RNA, and ligands.
  • •Isomorphic Labs has established strategic partnerships with major pharmaceutical firms like Eli Lilly and Novartis, with deal values potentially reaching billions in milestone payments, validating their commercial business model.
  • •The capital injection is intended to scale the company's wet-lab capabilities to create a 'closed-loop' system where AI predictions are rapidly validated through physical experimentation.

Competitor Analysis

Recursion Pharmaceuticals
Core Focus
AI-driven drug discovery
Key Differentiator
Large-scale automated wet-lab infrastructure
Insilico Medicine
Core Focus
Generative AI for drug design
Key Differentiator
End-to-end platform from target discovery to clinical trials
Exscientia
Core Focus
AI-designed drug candidates
Key Differentiator
Focus on precision engineering and clinical-stage assets

Technical Deep Dive

  • Architecture: Utilizes a transformer-based architecture evolved from AlphaFold 2, specifically optimized for multi-modal biological data integration.
  • Input Data: Incorporates structural data from the Protein Data Bank (PDB) combined with proprietary datasets covering small molecule interactions and genomic sequences.
  • Prediction Capabilities: Capable of predicting the 3D structures of complex biological assemblies, including protein-ligand, protein-DNA, and protein-RNA complexes.
  • Training Methodology: Employs a diffusion-based generative model to refine structural predictions, significantly improving accuracy in binding affinity modeling compared to previous iterations.

Future ImplicationsAI analysis grounded in cited sources

Isomorphic Labs will achieve a clinical-stage asset within 24 months.
The massive capital infusion allows for the rapid transition from in-silico discovery to physical validation and early-phase human trials.
Alphabet will increase its integration of Isomorphic's models into Google Cloud's life sciences offerings.
The participation of Alphabet in the funding round suggests a strategic alignment to monetize the underlying AI infrastructure through cloud-based enterprise services.

Timeline

2021-11
Alphabet announces the formation of Isomorphic Labs as a commercial spinout from DeepMind.
2024-01
Isomorphic Labs announces major multi-target drug discovery collaborations with Eli Lilly and Novartis.
2024-05
Google DeepMind unveils AlphaFold 3, which is integrated into Isomorphic Labs' research platform.
Read original article on 36氪

Weekly AI Recap

Read this week's curated digest of top AI events →

PostLinkedIn

AI-curated news aggregator. All content rights belong to original publishers.
Original source: 36氪 ↗

This is a summary, not the original. Read the source, or get the weekly briefing.

The weekly digest

One email a week. Unsubscribe anytime.